• Je něco špatně v tomto záznamu ?

Combined Pre- and Posttreatment of Paraoxon Exposure

DE. Lorke, SM. Nurulain, MY. Hasan, K. Kuča, GA. Petroianu

. 2020 ; 25 (7) : . [pub] 20200327

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012777

AIMS: Organophosphates (OPCs), useful agents as pesticides, also represent a serious health hazard. Standard therapy with atropine and established oxime-type enzyme reactivators is unsatisfactory. Experimental data indicate that superior therapeutic results can be obtained when reversible cholinesterase inhibitors are administered before OPC exposure. Comparing the protective efficacy of five such cholinesterase inhibitors (physostigmine, pyridostigmine, ranitidine, tacrine, or K-27), we observed best protection for the experimental oxime K-27. The present study was undertaken in order to determine if additional administration of K-27 immediately after OPC (paraoxon) exposure can improve the outcome. METHODS: Therapeutic efficacy was assessed in rats by determining the relative risk of death (RR) by Cox survival analysis over a period of 48 h. Animals that received only pretreatment and paraoxon were compared with those that had received pretreatment and paraoxon followed by K-27 immediately after paraoxon exposure. RESULTS: Best protection from paraoxon-induced mortality was observed after pretreatment with physostigmine (RR = 0.30) and K-27 (RR = 0.34). Both substances were significantly more efficacious than tacrine (RR = 0.67), ranitidine (RR = 0.72), and pyridostigmine (RR = 0.76), which were less efficacious but still significantly reduced the RR compared to the no-treatment group (paraoxon only). Additional administration of K-27 immediately after paraoxon exposure (posttreatment) did not further reduce mortality. Statistical analysis between pretreatment before paraoxon exposure alone and pretreatment plus K-27 posttreatment did not show any significant difference for any of the pretreatment regimens. CONCLUSIONS: Best outcome is achieved if physostigmine or K-27 are administered prophylactically before exposure to sublethal paraoxon dosages. Therapeutic outcome is not further improved by additional oxime therapy immediately thereafter.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012777
003      
CZ-PrNML
005      
20210507103631.0
007      
ta
008      
210420s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/molecules25071521 $2 doi
035    __
$a (PubMed)32230733
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Lorke, Dietrich E $u Department of Anatomy and Cellular Biology, College of Medicine and Health Sciences, Khalifa University, P O Box 127788, Abu Dhabi, UAE $u Herbert Wertheim College of Medicine, Department of Cellular Biology & Pharmacology, Florida International University, University Park GL 495, 11200 SW 8th St, Miami, FL 33199, USA
245    10
$a Combined Pre- and Posttreatment of Paraoxon Exposure / $c DE. Lorke, SM. Nurulain, MY. Hasan, K. Kuča, GA. Petroianu
520    9_
$a AIMS: Organophosphates (OPCs), useful agents as pesticides, also represent a serious health hazard. Standard therapy with atropine and established oxime-type enzyme reactivators is unsatisfactory. Experimental data indicate that superior therapeutic results can be obtained when reversible cholinesterase inhibitors are administered before OPC exposure. Comparing the protective efficacy of five such cholinesterase inhibitors (physostigmine, pyridostigmine, ranitidine, tacrine, or K-27), we observed best protection for the experimental oxime K-27. The present study was undertaken in order to determine if additional administration of K-27 immediately after OPC (paraoxon) exposure can improve the outcome. METHODS: Therapeutic efficacy was assessed in rats by determining the relative risk of death (RR) by Cox survival analysis over a period of 48 h. Animals that received only pretreatment and paraoxon were compared with those that had received pretreatment and paraoxon followed by K-27 immediately after paraoxon exposure. RESULTS: Best protection from paraoxon-induced mortality was observed after pretreatment with physostigmine (RR = 0.30) and K-27 (RR = 0.34). Both substances were significantly more efficacious than tacrine (RR = 0.67), ranitidine (RR = 0.72), and pyridostigmine (RR = 0.76), which were less efficacious but still significantly reduced the RR compared to the no-treatment group (paraoxon only). Additional administration of K-27 immediately after paraoxon exposure (posttreatment) did not further reduce mortality. Statistical analysis between pretreatment before paraoxon exposure alone and pretreatment plus K-27 posttreatment did not show any significant difference for any of the pretreatment regimens. CONCLUSIONS: Best outcome is achieved if physostigmine or K-27 are administered prophylactically before exposure to sublethal paraoxon dosages. Therapeutic outcome is not further improved by additional oxime therapy immediately thereafter.
650    _2
$a zvířata $7 D000818
650    _2
$a cholinesterasové inhibitory $x aplikace a dávkování $x toxicita $7 D002800
650    _2
$a reaktivátory cholinesterázy $x farmakologie $7 D002801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a organofosfáty $x toxicita $7 D010755
650    _2
$a oximy $x aplikace a dávkování $x chemie $7 D010091
650    _2
$a paraoxon $x chemie $x toxicita $7 D010261
650    _2
$a fysostigmin $x aplikace a dávkování $x chemie $7 D010830
650    _2
$a postexpoziční profylaxe $7 D056990
650    _2
$a preexpoziční profylaxe $7 D065129
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a pyridostigmin-bromid $x aplikace a dávkování $x chemie $7 D011729
650    _2
$a ranitidin $x chemie $x farmakologie $7 D011899
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a analýza přežití $7 D016019
650    _2
$a takrin $x aplikace a dávkování $x chemie $7 D013619
655    _2
$a časopisecké články $7 D016428
700    1_
$a Nurulain, Syed M $u Bio Science Department, COMSATS Institute of Information Technology, Bio Sciences Block, CUI, Park Road, Tarlai Kalan, Islamabad 45550, Pakistan
700    1_
$a Hasan, Mohamed Y $u Department of Pharmacology & Therapeutics, College of Medicine and Health Sciences, UAE University, Al Ain 15551, UAE
700    1_
$a Kuča, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanského 62/26, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Petroianu, Georg A $u Herbert Wertheim College of Medicine, Department of Cellular Biology & Pharmacology, Florida International University, University Park GL 495, 11200 SW 8th St, Miami, FL 33199, USA $u Department of Pharmacology, College of Medicine and Health Sciences, Khalifa University, P O Box 127788, Abu Dhabi, UAE
773    0_
$w MED00180394 $t Molecules (Basel, Switzerland) $x 1420-3049 $g Roč. 25, č. 7 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32230733 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507103630 $b ABA008
999    __
$a ok $b bmc $g 1651024 $s 1133156
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 25 $c 7 $e 20200327 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Možnosti archivace